Valuation of Innovative Drugs

Go Back

The value of medical innovation varies by stakeholder perspective. Registration authorities focus on clinical value for patients. Payers focus on economic value, including equity, and reward value to incentivize optimal innovation. Sustainable value-based pricing must also meet investor needs. We explore these perspectives, focusing on orphan diseases and, specifically, cell and gene therapies.